» Articles » PMID: 31481612

Decreased Humoral Immunity to Mumps in Young Adults Immunized with MMR Vaccine in Childhood

Abstract

In the past decade, multiple mumps outbreaks have occurred in the United States, primarily in close-contact, high-density settings such as colleges, with a high attack rate among young adults, many of whom had the recommended 2 doses of mumps-measles-rubella (MMR) vaccine. Waning humoral immunity and the circulation of divergent wild-type mumps strains have been proposed as contributing factors to mumps resurgence. Blood samples from 71 healthy 18- to 23-year-old college students living in a non-outbreak area were assayed for antibodies and memory B cells (MBCs) to mumps, measles, and rubella. Seroprevalence rates of mumps, measles, and rubella determined by IgG enzyme-linked immunosorbent assay (ELISA) were 93, 93, and 100%, respectively. The index standard ratio indicated that the concentration of IgG was significantly lower for mumps than rubella. High IgG avidity to mumps Enders strain was detected in sera of 59/71 participants who had sufficient IgG levels. The frequency of circulating mumps-specific MBCs was 5 to 10 times lower than measles and rubella, and 10% of the participants had no detectable MBCs to mumps. Geometric mean neutralizing antibody titers (GMTs) by plaque reduction neutralization to the predominant circulating wild-type mumps strain (genotype G) were 6-fold lower than the GMTs against the Jeryl Lynn vaccine strain (genotype A). The majority of the participants (80%) received their second MMR vaccine ≥10 years prior to study participation. Additional efforts are needed to fully characterize B and T cell immune responses to mumps vaccine and to develop strategies to improve the quality and durability of vaccine-induced immunity.

Citing Articles

Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity.

Anichini G, Terrosi C, Alessandri G, Miceli G, Borrelli E, Fabrizi S J Med Virol. 2024; 96(12):e70135.

PMID: 39722553 PMC: 11669888. DOI: 10.1002/jmv.70135.


Structure-based design of glycoprotein subunit vaccines for mumps.

Loomis R, Lai Y, Sowers S, Fisher B, Derrien-Colemyn A, Ambrozak D Proc Natl Acad Sci U S A. 2024; 121(47):e2404053121.

PMID: 39527740 PMC: 11588112. DOI: 10.1073/pnas.2404053121.


Serologic Cross-Reactivity between the Mumps Virus Vaccine Genotype A Strain and the Circulating Genotype G Strain.

Shaikh S, Carpenter M, Lin L, Frost J, McLachlan E, Stein D Viruses. 2024; 16(9).

PMID: 39339910 PMC: 11437446. DOI: 10.3390/v16091434.


Serosurveillance for Measles and Rubella.

Brady A, El-Badry E, Padron-Regalado E, Escudero Gonzalez N, Joo D, Rota P Vaccines (Basel). 2024; 12(7).

PMID: 39066453 PMC: 11281569. DOI: 10.3390/vaccines12070816.


Characteristics of reported mumps cases in the United States: 2018-2023.

Tappe J, Leung J, Mathis A, Oliver S, Masters N Vaccine. 2024; 42(25):126143.

PMID: 39019661 PMC: 11457128. DOI: 10.1016/j.vaccine.2024.07.044.


References
1.
Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R . Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171(10):4969-73. DOI: 10.4049/jimmunol.171.10.4969. View

2.
Crotty S, Aubert R, Glidewell J, Ahmed R . Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods. 2004; 286(1-2):111-22. DOI: 10.1016/j.jim.2003.12.015. View

3.
Sanz-Moreno J, Limia-Sanchez A, Garcia-Comas L, Mosquera-Gutierrez M, Echevarria-Mayo J, Castellanos-Nadal A . Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine. 2005; 23(41):4921-5. DOI: 10.1016/j.vaccine.2005.05.018. View

4.
Mauldin J, Carbone K, Hsu H, Yolken R, Rubin S . Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J Clin Microbiol. 2005; 43(9):4847-51. PMC: 1234049. DOI: 10.1128/JCM.43.9.4847-4851.2005. View

5.
Amanna I, Carlson N, Slifka M . Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007; 357(19):1903-15. DOI: 10.1056/NEJMoa066092. View